ALT logo

Altimmune Inc. (ALT)

$2.08

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ALT

Market cap

$404596818

EPS

-0.77

P/E ratio

--

Price to sales

16377.14

Dividend yield

--

Beta

0.155213

Price on ALT

Previous close

$1.97

Today's open

$1.97

Day's range

$1.95 - $2.10

52 week range

$1.91 - $6.44

Profile about ALT

CEO

Jerome Durso

Employees

57

Headquarters

Gaithersburg, MD

Exchange

NASDAQ Global Market

Shares outstanding

194517701

Issue type

Common Stock

ALT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ALT

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that it will report its third quarter 2026 financial results on Thursday, November 12, 2026.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)

news source

GlobeNewsWire • Nov 5, 2026

news preview

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph.D.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new clinical and preclinical data on pemvidutide will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

news source

GlobeNewsWire • Oct 19, 2026

news preview

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.

news source

MarketBeat • Oct 1, 2026

news preview

Altimmune to Participate in Stifel Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.

news source

GlobeNewsWire • Sep 23, 2026

news preview

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Sep 11, 2026

news preview

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.

news source

GlobeNewsWire • Sep 3, 2026

news preview

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

news source

Zacks Investment Research • Aug 19, 2026

news preview

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

news source

Zacks Investment Research • Aug 19, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Altimmune Inc.

Open an M1 investment account to buy and sell Altimmune Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ALT on M1